Iterum Therapeutics sees cash runway into 2026

Cash and cash equivalents were $12.7 million as of March 31, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of March 31, 2025, together with $1.0 million of net proceeds raised under its at-the-market offering program from April 1, 2025 through April 22, 2025 and net proceeds of $4.2 million from the Registered Direct Offering that closed April 30, 2025, will be sufficient to fund its operations into 2026. The foregoing estimate gives effect to Iterum’s currently planned pre-commercialization activities and potential commercial launch of ORLYNVAH by the fourth quarter of 2025. As of May 12, 2025, Iterum had approximately 40.0 million ordinary shares outstanding.